WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
WHO ’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countriesSince the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in global treatment guidelinesTwelfth Roche medicine or test to be prequalified Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confi...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
Vitamin C for 5 days is associated with decreased hospital mortality in sepsis subgroups: a nationwide cohort study
Background: Previous randomized trials of vitamin C, hydrocortisone, and thiamine on sepsis were limited by short-term vitamin C administration, heterogeneous populations, and the failure to evaluate each component ' s effect. The purpose of this study was to determine whether vitamin C alone for ≥ 5 days or in combination with corticosteroids and/or thiamine was associated with decreased mortality across the sepsis population and subpopulation.; Methods: Nationwide population-based study conducted using the Korean National Health Insurance Service database. A total of 384,282 adult patien ts with sepsis who were admitte...
Source: Current Awareness Service for Health (CASH) - February 10, 2022 Category: Consumer Health News Source Type: news
Real-World Corticosteroid Use in Severe Pneumonia Real-World Corticosteroid Use in Severe Pneumonia
Data from a real-world study provides insight into the benefits of corticosteroid therapy in severe cases of community-acquired pneumonia.Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2022 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19, DHSC (published/updated 31st January 2022)
Updated policy reflects tocilizumab is now licensed in the treatment of patients receiving systemic corticosteroids and require supplemental oxygen/mechanical ventilation. Sarilumab (off-label) should continue to be considered where tocilizumab is not available/cannot be used. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 1, 2022 Category: Consumer Health News Source Type: news
Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study, The Lancet Respiratory Medicine
Adults with asthma who had ≥2 oral corticosteroid courses in the past 2 years were at an increased risk of COVID-19 ICU admission or death (adjusted HR 1.27; 95% CI 1.09–1.48); authors suggest those with a recent asthma attack should be considered a priority group for boosters. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 17, 2022 Category: Consumer Health News Source Type: news
WHO recommends two new drugs to treat patients with COVID-19
The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids, says a WHO Guideline Development Group of international experts in The BMJ. (Source: World Pharma News)
Source: World Pharma News - January 17, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
Rapid test to support the American public ’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.EUA granted through Roche ’s participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program to bring rapid tests to the OTC marketBasel, 24 ...
Source: Roche Media News - December 24, 2021 Category: Pharmaceuticals Source Type: news
ICS Plus LABA Improves Lung Function in School-age Premature Kids ICS Plus LABA Improves Lung Function in School-age Premature Kids
Combining inhaled corticosteroids with long-acting beta-2-receptor agonists improves lung function in school-age children who were born prematurely, according to results of a randomized controlled trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 23, 2021 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news
Little Evidence to Support Use of Pricey Repository Corticotropin Little Evidence to Support Use of Pricey Repository Corticotropin
Repository corticotropin costs much more than corticosteroids, but shows little clinical benefit over them, results of a scoping review suggest.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 22, 2021 Category: Orthopaedics Tags: Rheumatology News Source Type: news
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Study met all primary and key secondary endpoints
Safety profile consistent with prior lebrikizumab studies in atopic dermatitis
Global regulatory submissions to occur next year based on data from the Phase 3 clinical trial program
INDIANAPOLIS,... Biopharmaceuticals, Dermatology Eli Lilly, lebrikizumab, atopic dermatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 21, 2021 Category: Pharmaceuticals Source Type: news
Do Long-term Low-Dose Steroids Increase Cardiovascular Risk? Do Long-term Low-Dose Steroids Increase Cardiovascular Risk?
Cardiologist Mauricio Wajngarten discusses results of a study looking at the association between cardiovascular risk and the long-term use of corticosteroids in patients with inflammatory disease.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2021 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news
The first case of fungal endogenous endophthalmitis caused by Aspergillus nidulans : Diagnostic and therapeutic challenge.
Conclusion: Although uncommon, we must consider Aspergillus as the causative organism in apparently immunocompetent patients with history of recent systemic corticosteroids treatment, especially if they suffer a broncopulmonary disorder. Aspergillus is an aggressive organism so a high index of suspicion along with early diagnosis and prompt treatment is the key for better outcomes. We highlight A. nidulans as the causative agent as there are no other reported cases. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 14, 2021 Category: Consumer Health News Source Type: news
